The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Published version of a preprint
Abstract
Purpose: Cancer-initiating cells (C-IC) have been described in multiple cancer types, including colorectal cancer. C-ICs are defined by their capacity to self-renew, thereby driving tumor growth. C-ICs were initially thought to be static entities; however, recent studies have determined these cells to be dynamic and influenced by microenvironmental cues such as hypoxia. If hypoxia drives the formation of C-ICs, then therapeutic targeting of hypoxia could represent a novel means to target C-ICs. Experimental Design: Patient-derived colorectal cancer xenografts were treated with evofosfamide, a hypoxia-activated prodrug (HAP), in combination with 5-fluorouracil (5-FU) or chemoradiotherapy (5-FU and radiation; CRT). Treatment groups included both concurrent and sequential dosing regimens. Effects on the colorectal cancer-initiating cell (CC-IC) fraction were assessed by serial passage in vivo limiting dilution assays. FAZA-PET imaging was utilized as a noninvasive method to assess intratumoral hypoxia. Results: Hypoxia was sufficient to drive the formation of CC-ICs and colorectal cancer cells surviving conventional therapy were more hypoxic and C-IC-like. Using a novel approach to combination therapy, we show that sequential treatment with 5-FU or CRT followed by evofosfamide not only inhibits tumor growth of xenografts compared with 5-FU or CRT alone, but also significantly decreases the CC-IC fraction. Furthermore, noninvasive FAZA-PET hypoxia imaging was predictive of a tumor's response to evofosfamide. Conclusions: Our data demonstrate a novel means to target the CC-IC fraction by adding a HAP sequentially after conventional adjuvant therapy, as well as the use of FAZA-PET as a biomarker for hypoxia to identify tumors that will benefit most from this approach. Clin Cancer Res; 24(9); 2116–27. ©2018 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“evofosfamide was shown to effectively reduce CRC tumor growth and CSC numbers when administered sequentially after 5-FU treatment [217].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [217]
Citations
Cites
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“Despite a significant body of evidence linking intratumoral hypoxia to poor prognosis, therapeutic resistance, and enrichment of C-ICs, targeting hypoxia has yet to become standard of care in cancer treatment (1, 4, 22).”
BackgroundWnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M. K., Ng, K., Ma, J., Wienholds, E., Dunant, C., et al. (2013) · Science · doi:10.1126/science.1227670 · Cited by 744
Self-citationHypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Rockwell, S., Dobrucki, I., Kim, E., Marrison, S., & Vu, V. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167087 · Cited by 511
Self-renewal as a therapeutic target in human colorectal cancer
Kreso, A., van Galen, P., Pedley, N. M., Lima-Fernandes, E., Frelin, C., Davis, T., Cao, L., Baiazitov, R., Du, W., Sydorenko, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3418 · Cited by 500
Self-citationCancer Stem Cells in Radiation Resistance
Rich, J. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0895 · Cited by 496
Cited by
Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance
Najafi, M., Farhood, B., Mortezaee, K., Kharazinejad, E., Majidpoor, J., & Ahadi, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03080-1 · Cited by 161
Gao, S., Soares, F., Wang, S., Wong, C. C., Chen, H., Yang, Z., Liu, W., Go, M. Y. Y., Ahmed, M., Zeng, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01882-7 · Cited by 105
Self-citationMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, evofosfamide was shown to effectively reduce CRC tumor growth and CSC numbers when administered sequentially after 5-FU treatment [217].”
Self-citationThe Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Li, Y., Zhao, L., & Li, X.-F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.636892 · Cited by 75
Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells
Chen, X., Niu, W., Fan, X., Yang, H., Zhao, C., Fan, J., Yao, X., & Fang, Z. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac157 · Cited by 62
Metadata
- Authors
- Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., Vines, D. C., Haibe-Kains, B., Wouters, B. G., Metser, U., Jaffray, D. A., Smith, M., & O'Brien, C. A.
- Affiliations
- University Health Network (CA)
- 4Structural Genomics Consortium, Toronto, Ontario, Canada.
- 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Institute of Cancer Research (GB)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2018-04-30
- Volume
- 24
- Issue
- 9
- Pages
- 2116-2127
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2791469985
- Cited by
- 22
- References
- 51
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 1 · 2019: 3 · 2018: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Gouvernement du Canada | CIHR | Institute of Cancer Research (ICR)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- evofosfamide, hypoxia-activated prodrug, colorectal cancer, cancer stem cells, tumor hypoxia, 5-fluorouracil, chemoradiotherapy, sequential therapy, adjuvant therapy, limiting dilution assay, hypoxia markers, patient-derived xenografts
- MeSH terms
- Animals, Hypoxia, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Male, Nitroimidazoles, Phenotype, Phosphoramide Mustards, Prodrugs, Neoplastic Stem Cells, Colorectal Neoplasms, Biomarkers, Cell Hypoxia, Caspases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Positron-Emission Tomography, Mice, Standard of Care, Chemoradiotherapy, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1715
- The paper
- Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., Vines, D. C., Haibe-Kains, B., Wouters, B. G., Metser, U., Jaffray, D. A., Smith, M., & O'Brien, C. A. (2018). Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.